Key Points
- Insider Johannes Kastelein sold 50,246 NewAmsterdam Pharma shares at an average price of $25.03, generating approximately $1.26 million. His remaining ownership fell by 42.03% to 69,302 shares; he also sold 125,000 shares in August.
- NewAmsterdam shares opened at $23.20, near the lower end of their 52-week range of $21.02 to $42.21. The company recently reported a quarterly loss of $0.52 per share, missing estimates, despite revenue exceeding expectations.
- Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $49.73, while institutional investors own approximately 89.89% of the stock.
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) insider Johannes Kastelein sold 50,246 shares of the company's stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $25.03, for a total value of $1,257,657.38. Following the transaction, the insider directly owned 69,302 shares of the company's stock, valued at $1,734,629.06. This represents a 42.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Johannes Jacob Piete Kastelein also recently made the following trade(s):
- On Monday, August 24th, Johannes Kastelein sold 125,000 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $26.91, for a total value of $3,363,750.00.
NewAmsterdam Pharma Stock Performance
Shares of NewAmsterdam Pharma stock opened at $23.20 on Friday. The firm has a market cap of $2.77 billion, a PE ratio of -10.74 and a beta of 0.10. The business's 50 day simple moving average is $25.56 and its 200 day simple moving average is $30.23. NewAmsterdam Pharma Company N.V. has a 52-week low of $21.02 and a 52-week high of $42.21.
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.04). The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $2.83 million. NewAmsterdam Pharma had a negative return on equity of 34.81% and a negative net margin of 3,644.21%. As a group, equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current year.
Analyst Ratings Changes
Several research analysts recently commented on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. BMO Capital Markets assumed coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an "outperform" rating and a $58.00 price target on the stock. Royal Bank Of Canada cut their price target on shares of NewAmsterdam Pharma from $51.00 to $50.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. HC Wainwright reissued a "buy" rating and set a $52.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, September 8th. Finally, Jefferies Financial Group restated a "buy" rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, NewAmsterdam Pharma presently has a consensus rating of "Moderate Buy" and an average target price of $49.73.
View Our Latest Report on NAMS
Institutional Investors Weigh In On NewAmsterdam Pharma
Several large investors have recently made changes to their positions in NAMS. Frazier Life Sciences Management L.P. grew its stake in shares of NewAmsterdam Pharma by 6.8% in the second quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company's stock valued at $613,033,000 after buying an additional 1,145,128 shares in the last quarter. Capital World Investors increased its holdings in NewAmsterdam Pharma by 1.6% during the fourth quarter. Capital World Investors now owns 9,984,000 shares of the company's stock worth $350,239,000 after buying an additional 161,289 shares during the last quarter. Maverick Capital Ltd. raised its position in NewAmsterdam Pharma by 15.4% during the first quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company's stock worth $69,987,000 after acquiring an additional 292,176 shares in the last quarter. Castle Hook Partners LP bought a new stake in NewAmsterdam Pharma during the fourth quarter worth $38,062,000. Finally, First Turn Management LLC raised its position in NewAmsterdam Pharma by 24.6% during the fourth quarter. First Turn Management LLC now owns 893,473 shares of the company's stock worth $31,343,000 after acquiring an additional 176,502 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, with an emphasis on improving the treatment of dyslipidemia and reducing cardiovascular risk. The company's lead investigational product is obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor designed to lower low-density lipoprotein cholesterol and potentially address other lipid-related abnormalities.
Obicetrapib is being studied as an adjunct to existing lipid-lowering therapies, including in patients who have not achieved adequate cholesterol control and people with heterozygous familial hypercholesterolemia.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
